Table 2 BRCA1/2 Mutations in Older Triple Negative Breast Cancer
From: Therapeutic landscape in mutational triple negative breast cancer
Reference | Race/Ethnicity | TNBC cases | Total TNBC | TNBC (>50 years) | TNBC (>60 years) | |||
|---|---|---|---|---|---|---|---|---|
BRCA1 prevalence | BRCA2 prevalence | BRCA1 prevalence | BRCA2 prevalence | BRCA1 prevalence | BRCA2 prevalence | |||
Comen 2011 [11] | AJa | 64 | 29.7% (19/64) | 9.4% (6/64) | 13.9% (5/36) | 11.1% (4/36) | _ | _ |
Hartman 2012 [79] | Caucasian/Hispanic/AAb/Asian | 199 | 6.5% (13/199) | 4.0% (8/199) | 4.4% (5/113) | 2.7% (3/113) | _ | _ |
Greenup 2013 [13] | Caucasian/Hispanic/AA/Asian/AJ | 450 | 23.5% (106/450) | 7.1% (32/450) | 14.9% (25/168) | 7.7% (13/168) | 5.3% (2/38) | 7.9% (3/38) |
Sharma 2014 [80] | Caucasian/AA/AJ | 207 | 11.1% (23/207) | 4.3% (9/207) | BRCA1/2 prevalence 8.4%(11/131) | BRCA1/2 prevalence 4.9%(3/62) | ||
Couch 2015 [6] | Caucasian/Hispanic/AA/Asian | 1824 | 8.5% (155/1824) | 2.7% (49/1824) | 3.3% (17/520) | 1.3% (7/520) | 1.4% (4/279) | 0.7% (2/279) |
Wong 2015 [82] | Australian | 439 | 5.9% (26/439) | 3.4% (15/439) | 2.1% (6/286) | 3.5% (10/286) | 2.2% (4/182) | 2.2% (4/182) |
Wong 2015 [82] | Polish | 335 | 5.4% (18/335) | 4.5% (15/335) | 3.5% (10/286) | 4.5% (13/286) | 2.1% (3/141) | 4.3% (6/141) |
Gonzalez 2016 [83] | Caucasian/Hispanic/AA/Asian | 105 | 12.4% (13/105) | 1.9% (2/105) | 3.8% (2/52) | 1.9% (1/52) | _ | _ |
Zhang 2016 [84] | Chinese | 990 | 7.2% (71/990) | 2.2% (22/990) | 3.7% (18/492) | _ | _ | _ |